News Sentiment

UTHR sentiment intelligence

United Therapeutics Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 65 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 547.06 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 65

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-1.6% over one week, +0.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Is United Therapeutics a "Quant King" Favorite for a Reason

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction -1.6% Price digesting
Trend fit Trend active 0.2% over four weeks
Fair value 56.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 25
Neutral 37
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 65
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Investing.com Canada 7
Market source 7
Investing.com 6
Moomoo 4
MT Newswires 4
Quartr 4
simplywall.st 4
Stock Titan 3

Event Lens

What the news is about

Classified themes
Market update 43
Earnings 6
Deals and strategy 6
Regulatory and legal 5
Balance sheet 4
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 65
Investing.com Direct company coverage

United Therapeutics CEO Rothblatt sells $5.2m in company stock

Martine A. Rothblatt, CEO of United Therapeutics Corp., sold approximately $5.2 million worth of company stock through a pre-arranged trading plan, following an 88% surge in share value over the past year. These sales occurred after she exercised stock options worth about $1.28 m

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 14:10
Source
Investing.com
The Business Journals Direct company coverage

RTP drugmaker strikes $300M deal for Massachusetts company

United Therapeutics, based in Research Triangle Park, has acquired Massachusetts-based Thymmune for $300 million. This acquisition marks a significant expansion for United Therapeutics into regenerative medicine and organ transplants. The deal was reported by Zac Ezzone of the Tr

Tone
Positive 70/100
Event
Deals and strategy
Published
06 Jul 2026 22:39
Source
The Business Journals
Moomoo Direct company coverage

Press Release: United Therapeutics Corporation Acquires Thymmune Therapeutics

United Therapeutics Corporation has announced the acquisition of Thymmune Therapeutics. The terms of the acquisition, including the financial details and strategic implications for both companies, are expected to be elaborated upon in the full press release. This move signifies U

Tone
Positive 68/100
Event
Deals and strategy
Published
02 Jul 2026 22:39
Source
Moomoo
The Business Journals Direct company coverage

United Therapeutics buys Massachusetts biotech Thymmune Therapeutics for $140M

United Therapeutics has acquired Thymmune Therapeutics for $140 million, a move that aligns with United Therapeutics' mission to enhance organ health and transplants. The acquisition occurred shortly after United Therapeutics received FDA premarket approval for a lung transplant

Tone
Positive 72/100
Event
Deals and strategy
Published
02 Jul 2026 20:11
Source
The Business Journals
The Business Journals Direct company coverage

Thymmune Therapeutics acquired by Maryland biotech for $140M

Thymmune Therapeutics has been acquired by United Therapeutics for $140 million. This acquisition, which closed on Thursday, integrates Thymmune's thymus cell therapy platform with United Therapeutics' focus on lung disease treatments and pig-to-human transplant research. The dea

Tone
Positive 71/100
Event
Deals and strategy
Published
02 Jul 2026 19:35
Source
The Business Journals
grafa.com Direct company coverage

United Therapeutics acquires Thymmune for $140 million

United Therapeutics (NASDAQ:UTHR) has acquired Thymmune Therapeutics for $140 million in cash, with potential additional milestone payments of up to $160 million. Thymmune specializes in preclinical regenerative thymic cell therapies for immune-related diseases, including THY-100

Tone
Positive 72/100
Event
Balance sheet
Published
02 Jul 2026 14:11
Source
grafa.com
Stock Titan Direct company coverage

United Therapeutics buys Thymmune, adding thymus cell therapy platform

United Therapeutics (NASDAQ: UTHR) has acquired Thymmune Therapeutics for $140 million in cash, with potential earn-out payments of up to $160 million. Thymmune specializes in scalable, regenerative thymic cell therapies derived from induced pluripotent stem cells (iPSC), aimed a

Tone
Positive 73/100
Event
Balance sheet
Published
02 Jul 2026 10:11
Source
Stock Titan
www.marketscreener.com Direct company coverage

United Therapeutics Corporation acquired Thymmune Therapeutics, Inc. for $300 million.

United Therapeutics Corporation (NasdaqGS:UTHR) has acquired Thymmune Therapeutics, Inc. for a total consideration of $300 million. The acquisition includes an upfront payment of $140 million in cash, with an additional potential $160 million in earn-out payments tied to clinical

Tone
Positive 71/100
Event
Deals and strategy
Published
02 Jul 2026 08:40
Source
www.marketscreener.com
Investing.com Nigeria Direct company coverage

United Therapeutics chairperson & CEO Rothblatt sells $5.18m stock By Investing.com

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, sold 9,500 shares of the company’s common stock for approximately $5.18 million. This transaction followed the exercise of stock options and was conducted under a pre-arranged 10b5-1 trading plan. Despite the in

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:11
Source
Investing.com Nigeria
PR Newswire Direct company coverage

The Oliver Patch Project Announces United Therapeutics Corporation Named Visionary/Presenting Sponsor of National Patch Day 2026

The Oliver Patch Project has announced that United Therapeutics Corporation will be the Visionary/Presenting Sponsor for National Patch Day 2026. This initiative aims to spread hope and encouragement to children, teens, and young adults nationwide who are facing cancer, serious i

Tone
Positive 70/100
Event
Market update
Published
01 Jul 2026 13:39
Source
PR Newswire
United Therapeutics Investor Relations Direct company coverage

United Therapeutics Corporation Acquires Thymmune Therapeutics

United Therapeutics Corporation has acquired Thymmune Therapeutics for $140 million in cash, plus potential earn-out payments of up to $160 million. Thymmune specializes in scalable, regenerative thymic cell therapies for conditions like post-transplant organ tolerance, immunodef

Tone
Positive 71/100
Event
Balance sheet
Published
01 Jul 2026 00:12
Source
United Therapeutics Investor Relations
www.marketscreener.com Direct company coverage

United Therapeutics Insider Sold Shares Worth $5,167,734, According to a Recent SEC Filing

An insider at United Therapeutics Corporation recently sold shares totaling $5,167,734, as disclosed in a recent SEC filing. The article, however, is reserved for members only, requiring registration to access the full details of the transaction. United Therapeutics develops and

Tone
Negative 37/100
Event
Market update
Published
30 Jun 2026 19:39
Source
www.marketscreener.com
Medtech Insight Direct company coverage

FDA Approves United Therapeutics’ LungFX For Centralized Lung Perfusion, On A Narrow Indication

The FDA has approved United Therapeutics' LungFX for centralized lung perfusion. The approval is specifically for a narrow indication, highlighting the targeted application of this medical device. This development is significant for the field of respiratory medicine.

Tone
Positive 76/100
Event
Regulatory and legal
Published
30 Jun 2026 13:09
Source
Medtech Insight